CYPRESS BIOSCIENCE INC
EXHIBIT 10.25
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>6
<FILENAME>a2131468zex-10_25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04SAN1113_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_lq1113_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="lq1113_exhibit_10.25"> </A>
<A NAME="toc_lq1113_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.25    <BR>    </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>***Text Omitted and Filed Separately<BR>
Confidential Treatment Requested<BR>
Under 17 C.F.R. &sect;&sect;200.80(b)(4)<BR>
and 240.24B-2  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> PURCHASE AND SUPPLY AGREEMENT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THIS PURCHASE AND SUPPLY AGREEMENT (</B></FONT><FONT SIZE=2>this </FONT><FONT SIZE=2><B><I>"Agreement"</I></B></FONT><FONT SIZE=2>) is made and
entered into as of January&nbsp;9, 2004 (the </FONT><FONT SIZE=2><B><I>"Effective Date"</I></B></FONT><FONT SIZE=2>), by and between </FONT><FONT SIZE=2><B>PIERRE FABRE
M&Eacute;DICAMENT</B></FONT><FONT SIZE=2>, organized under the laws of France having an address of 45, place Abel-Gance, 92654 Boulogne Cedex, France
(</FONT><FONT SIZE=2><B><I>"Pierre Fabre"</I></B></FONT><FONT SIZE=2>), and </FONT><FONT SIZE=2><B>CYPRESS BIOSCIENCE,&nbsp;INC.</B></FONT><FONT SIZE=2>, a Delaware corporation having an address of 4350
Executive Drive, Suite 325, San Diego, CA 92121, U.S.A. (</FONT><FONT SIZE=2><B><I>"Cypress"</I></B></FONT><FONT SIZE=2>). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>RECITALS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Pierre Fabre owns or controls certain patents and valuable know-how related to the compound
Milnacipran (as defined below) and the Licensed Product (as defined below); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Pierre Fabre and Cypress entered into the Third Restated License Agreement, dated as of the date hereof, as amended (the </FONT> <FONT SIZE=2><B><I>"Restated License Agreement"</I></B></FONT><FONT SIZE=2>),
pursuant to which Pierre Fabre granted to Cypress an exclusive license to develop, register, manufacture from the API (as
defined below), use, distribute, sell, offer for sale, have sold and import the Licensed Product in any and all indications in the Licensed Territory (as defined below); </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Pierre Fabre also granted Cypress a license to certain trademarks pursuant to the First Restated Trademark License Agreement,
dated as of the date hereof, as amended, between Cypress and Pierre Fabre; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Pierre Fabre and Cypress desire to enter into this Agreement to set forth the terms upon which Pierre Fabre will supply to
Cypress and its sub-licensees, and Cypress and its sub-licensees will purchase from Pierre Fabre, the Bulk API (as defined below) manufactured in compliance with all applicable
requirements set forth herein. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOW, THEREFORE,</B></FONT><FONT SIZE=2> in consideration of the foregoing premises and the mutual covenants and agreements contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </FONT></P>

<P><FONT SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized terms used but not otherwise defined in this Agreement will have the meanings given such terms in the Restated License Agreement. Other capitalized
terms will have the meanings set forth below. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.1&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Action"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;9.2(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.2&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Affiliate"</I></B></FONT><FONT SIZE=2> shall mean any company or entity controlled by, controlling, or under common control
with a party hereto. For this purpose, the term "control" shall mean the direct or indirect ownership of at least 50% of the voting stock of that corporation, or in the absence of ownership of at
least 50% of the voting stock of that corporation, the power, directly or indirectly to cause the direction of the management and policies of such corporation. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.3&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Annual Excess"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;5.1(a)(iii). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.4&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"API"</I></B></FONT><FONT SIZE=2> shall mean the active pharmaceutical ingredient Milnacipran contained in the Licensed
Product. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=481226,FOLIO='1',FILE='DISK043:[04SAN3.04SAN1113]LQ1113A.;6',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lq1113_1_2"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.5&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"API Specifications"</I></B></FONT><FONT SIZE=2> means those specifications pertaining to the API set forth in the IND for
the Licensed Product filed by Cypress with the FDA in the United States (No.&nbsp;63736), and in the DMF filed by Pierre Fabre with the FDA (N<SUP>o</SUP>11501), as described in </FONT> <FONT SIZE=2><B>Exhibit&nbsp;I</B></FONT><FONT SIZE=2> hereto
and made a part hereof, as modified to comply with the NDA for the Licensed Product or otherwise modified from time to time in
accordance with Section&nbsp;8.3. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.6&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Buffer Stock"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.9(a). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.7&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Bulk API"</I></B></FONT><FONT SIZE=2> shall mean API in bulk form. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.8&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Certificate of Analysis"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;7.3(d). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.9&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"cGMPs"</I></B></FONT><FONT SIZE=2> shall mean the standards established by the FDA for current Good Manufacturing Practices,
as specified in the Quality System Regulations set forth at 21 CFR Parts 210 and 211. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.10&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Change of Control"</I></B></FONT><FONT SIZE=2> shall mean (i)&nbsp;a sale, lease or other disposition of
all or substantially all of the assets of Cypress; (ii)&nbsp;a merger or consolidation of Cypress in which the holders of Cypress' outstanding voting stock immediately prior to such transaction own,
immediately after such transaction, securities representing less than 50% of the voting power of Cypress or Cypress' parent or, if Cypress is not the surviving entity, any other entity surviving such
transaction or the surviving entity's parent; or (iii)&nbsp;an acquisition by any person, entity or group within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act, or any comparable
successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by Cypress or any entity controlled by Cypress) of the beneficial ownership (within the meaning of
Rule&nbsp;13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of Cypress representing at least 50% of the combined voting power entitled to vote in the
election of directors; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that clause&nbsp;(ii) shall not apply to a merger effected exclusively for the purpose of changing the
domicile of Cypress or the name of Cypress. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.11&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Collaboration Agreement"</I></B></FONT><FONT SIZE=2> shall mean that certain License and Collaboration
Agreement between Cypress and Forest, dated as of the Effective Date, a copy of which has been provided to Pierre Fabre, as may be amended, modified or restated from time to time, pursuant to which,
among other things, Cypress has granted to Forest a sub-license to the Licensed Technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.12&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Commercially Reasonable Efforts"</I></B></FONT><FONT SIZE=2> shall mean that the parties shall conform to the
standards of diligence customary in the pharmaceutical industry, with respect to compounds having commercial potential comparable to Milnacipran, in fulfilling their applicable obligations under this
Agreement with regard to manufacturing or otherwise. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.13&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Confidential Information"</I></B></FONT><FONT SIZE=2> shall mean any confidential information (including,
without limitation, Information) furnished to it by the other party pursuant to the Restated License Agreement or this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.14&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Conform"</I></B></FONT><FONT SIZE=2> shall mean that a quality control sample or batch delivery of Bulk API
meets the API Specifications and was manufactured in accordance with the requirements of Section&nbsp;8.1. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.15&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Control"</I></B></FONT><FONT SIZE=2> shall mean, with respect to any Information or intellectual property
right, possession by a party of the ability (whether by ownership, license or otherwise, other than any license granted under this Agreement) to grant access, a license or sub-license to
such Information or intellectual property right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party as of the time such party would first be
required hereunder to grant the other party such access, license or sublicense, or at any other time during the term of such access, license or sublicense. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.16&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Correction Plan"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.9(c). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.17&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Current Buffer Stock"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.9(c). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=121787,FOLIO='2',FILE='DISK043:[04SAN3.04SAN1113]LQ1113A.;6',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lq1113_1_3"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.18&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Cypress Indemnitees"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;9.2(b). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.19&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Date of First Commercial Sale"</I></B></FONT><FONT SIZE=2> shall mean the actual date of first commercial
sale of a Licensed Product in the Licensed Territory. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.20&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Delivery Forecast"</I></B></FONT><FONT SIZE=2> shall mean a forecast provided by Cypress and/or its
sub-licensees of the quantity of Bulk API required by Cypress and its sub-licensees during the applicable period (including supplies for formulation development, clinical
trials and sampling). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.21&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"DMF"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.6. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.22&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Effective Date"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in the introductory paragraph. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.23&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Estimated Date of First Commercial Sale"</I></B></FONT><FONT SIZE=2> shall mean the estimated Date of First
Commercial Sale of a Licensed Product in the Licensed Territory, as may be established from time to time by Cypress pursuant to this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.24&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Exchange Act"</I></B></FONT><FONT SIZE=2> shall mean the Securities and Exchange Act of 1934, as amended. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.25&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Exercise Date"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.11(b). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.26&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"FDA"</I></B></FONT><FONT SIZE=2> shall mean the United States Food and Drug Administration. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.27&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"FD&amp;C Act"</I></B></FONT><FONT SIZE=2> shall mean the United States Food, Drug and Cosmetic Act. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.28&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"First Commercial Sale"</I></B></FONT><FONT SIZE=2> shall mean the first commercial sale of the first Licensed
Product in the first country within the Licensed Territory. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.29&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Forest"</I></B></FONT><FONT SIZE=2> shall mean Forest Laboratories Ireland Limited, an Irish corporation and
a wholly owned subsidiary of Forest Laboratories,&nbsp;Inc., a Delaware corporation. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.30&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Generic Product"</I></B></FONT><FONT SIZE=2> shall mean Licensed Product commercialized as a generic product
by Cypress or any of its sub-licensees or any Third Party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.31&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Generic Supplier"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.12. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.32&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Indemnified Party"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;9.3(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.33&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Indemnifying Party"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;9.3(a). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.34&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Index"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;5.1(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.35&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Information"</I></B></FONT><FONT SIZE=2> shall mean all tangible and intangible (a)&nbsp;techniques,
technology, practices, trade secrets, inventions (whether or not patentable), methods, manufacturing processes, knowledge, know-how, skill, experience, test data and results (including
pharmacological, toxicological and clinical test data and results), analytical and quality control data, results or descriptions and software, (b)&nbsp;compounds, compositions of matter, cells, cell
lines, assays, and physical, biological or chemical material, and (c)&nbsp;marketing data, including clinical studies designed to support promotional efforts, relating to API or to the Licensed
Product in any indication. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.36&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Letter Agreement"</I></B></FONT><FONT SIZE=2> shall mean the agreement to be entered into among Pierre Fabre,
Cypress and Forest as of the Restatement Date, as may be amended. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.37&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"License Effective Date"</I></B></FONT><FONT SIZE=2> shall mean August&nbsp;1, 2001. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.38&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Licensed Product"</I></B></FONT><FONT SIZE=2> shall mean any product (including a Cypress Product or product
containing a Cypress Formulation or Forest Formulation) containing Milnacipran as an active ingredient, in any formulation and through any mode of administration, that incorporates or uses the
Licensed Technology or the manufacture, use or sale of which Licensed Product is otherwise within the scope of any claim of the Pierre Fabre Patents. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=1019460,FOLIO='3',FILE='DISK043:[04SAN3.04SAN1113]LQ1113A.;6',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lq1113_1_4"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.39&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Licensed Technology"</I></B></FONT><FONT SIZE=2> shall mean the Pierre Fabre Patents and the Pierre Fabre
Know-How. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.40&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Licensed Territory"</I></B></FONT><FONT SIZE=2> shall mean the United States of America, its territories and
possessions and Canada and, if extended pursuant to Section&nbsp;2.2 of the Restated License Agreement, countries that are members of the European Union and Japan. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.41&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Losses"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Sections 9.2(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.42&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Manufacturing Know-How"</I></B></FONT><FONT SIZE=2> shall mean all data, Information and
know-how in the possession of Pierre Fabre prior to the License Effective Date or developed or acquired by or for Pierre Fabre thereafter and relating to the manufacture of API. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.43&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Manufacturing Process"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.3. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.44&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Manufacturing Right"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.11(b). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.45&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Maximum Time Before Retesting"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in
Section&nbsp;7.1. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.46&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Milnacipran"</I></B></FONT><FONT SIZE=2> shall mean the substance known as milnacipran (INN), which expressly
excludes any analogs, derivatives and enantiomers of milnacipran (INN). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.47&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Minimum Buffer Stock"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.9(b). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.48&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Minimum Time to Retesting"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in
Section&nbsp;7.1. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.49&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"NDA"</I></B></FONT><FONT SIZE=2> shall mean a New Drug Application and all amendments and supplements thereto
filed with the FDA (as more fully defined in 21 C.F.R. 314.5 et seq.), or the equivalent application filed with any equivalent agency or governmental authority outside the United States (including any
supra-national agency such as in the European Union) requiring such filing, including all documents, data and other information concerning a pharmaceutical product that are necessary for obtaining
Regulatory Approval to market and sell such pharmaceutical product. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.50&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Other Changes"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.3. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.51&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Outsourcing Notice</I></B></FONT><FONT SIZE=2>" shall have the meaning set forth in Section&nbsp;8.12. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.52&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Patent"</I></B></FONT><FONT SIZE=2> shall mean (a)&nbsp;valid and enforceable patents,
re-examinations, reissues, renewals, confirmations, extensions (including supplemental protection certificates) and term restorations, and (b)&nbsp;pending applications for patents,
including, without limitation, continuations, continuations-in-part, provisionals, divisionals and substitute applications, including, without limitation, inventors'
certificates. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.53&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Pierre Fabre Indemnitees"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in
Section&nbsp;9.2(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.54&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Pierre Fabre Know-How"</I></B></FONT><FONT SIZE=2> shall mean Information that is Controlled by
Pierre Fabre or its Affiliates that is not covered by the Pierre Fabre Patents but is related to the API or the Licensed Product. The Pierre Fabre Know-How includes, without limitation,
the Information described on Exhibit&nbsp;A to the Restated License Agreement. Pierre Fabre Know-How shall exclude Manufacturing Know-How. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.55&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Pierre Fabre Patents"</I></B></FONT><FONT SIZE=2> shall mean all Patents Controlled by Pierre Fabre or any of
its Affiliates that are necessary or useful for the development, manufacture or commercialization of Milnacipran and the Licensed Product in the Licensed Territory. The Pierre Fabre Patents include,
without limitation, the Patents set forth on Exhibit&nbsp;B to the Restated License Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.56&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Pierre Fabre Suppliers"</I></B></FONT><FONT SIZE=2> shall include all Third Parties that supply Raw Materials
to Pierre Fabre. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.57&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Postponement"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;4.2. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.58&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Pre-Approved Changes"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in
Section&nbsp;8.3. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=19050,FOLIO='4',FILE='DISK043:[04SAN3.04SAN1113]LQ1113A.;6',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lq1113_1_5"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.59&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Purchase Order"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;4.1(b)(i). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.60&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Quality Agreement"</I></B></FONT><FONT SIZE=2> shall mean an agreement between the parties that describes the
parties' quality control, quality assurance and regulatory responsibilities relating to the manufacture and supply of Bulk API. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.61&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Raw Materials"</I></B></FONT><FONT SIZE=2> shall mean the materials used in manufacturing Bulk API. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.62&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Regulatory Approval"</I></B></FONT><FONT SIZE=2> shall mean any and all approvals (including price and
reimbursement approvals), licenses, registrations, or authorizations of health/regulatory authorities or any country, federal, state or local regulatory agency, department, bureau or other government
entity that is legally required or necessary from an economic point of view for the manufacture, use, storage, import, transport and/or sale of a Licensed Product in such jurisdiction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.63&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Restated License Agreement"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in the second
recital. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.64&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Rest of the World"</I></B></FONT><FONT SIZE=2> shall mean the entire world excluding the Licensed Territory. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.65&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Samples"</I></B></FONT><FONT SIZE=2> shall mean quantities of the Licensed Product given to authorized
medical professionals free of charge as part of the marketing, advertising or promotion of the Licensed Product. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.66&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Second Source Facility"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.10. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.67&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Shared Amount"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;5.1(b). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.68&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Shortfall"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;8.9(c). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.69&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Starting Materials"</I></B></FONT><FONT SIZE=2> shall mean those materials that are starting materials within
the meaning of the guideline for submitting supporting documentation in drug applications for the manufacture of drug substances FDA/CDER 02 1987, as may be amended. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.70&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Term"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;10.1. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.71&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Third Party"</I></B></FONT><FONT SIZE=2> shall mean any entity other than Cypress or Pierre Fabre or an
Affiliate of Cypress or Pierre Fabre. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.72&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Transfer Price"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;5.1(a). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.73&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>"Working Group"</I></B></FONT><FONT SIZE=2> shall have the meaning set forth in Section&nbsp;3.1. </FONT></P>


<P><FONT SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PURCHASE AND SUPPLY OF API.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;&nbsp;&nbsp;Supply by Pierre Fabre.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre agrees that it will manufacture and supply to Cypress and its
sub-licensees such quantities of Bulk API as requested by Cypress and/or its sub-licensees pursuant to Section&nbsp;4 to cover their total market needs for the Licensed
Territory. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;&nbsp;&nbsp;Exclusive Supplier.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;During the Term, subject to Sections 8.11 and 8.12, Pierre Fabre will be the exclusive supplier to Cypress and its
sub-licensees of Bulk API, and Cypress agrees that it and its sub-licensees shall purchase from Pierre Fabre all of their requirements of Bulk API, for clinical trials, samples
and commercial sales of the Licensed Product in the Licensed Territory. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=35075,FOLIO='5',FILE='DISK043:[04SAN3.04SAN1113]LQ1113A.;6',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_lr1113_1_6"> </A> </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;In the event Pierre Fabre is unable to supply to Cypress or its sub-licensee API requested in a Purchase
Order, in whole or part, due to a shortage of production capacity or Raw Materials for any reason (except to the extent caused by Cypress or any of its sub-licensees), then, in addition to
any other rights that may be available to Cypress under this Agreement, Pierre Fabre shall promptly notify Cypress and/or its sub-licensees, in writing, of such shortage of production
capacity or Raw Materials, and, if possible, the date such shortage of production capacity or Raw Materials is expected to end. In such event, without limiting the provisions of Section&nbsp;6,
Pierre Fabre shall allocate its available production capacity and/or Raw Materials for the production of API in a manner proportional to the utilization by all customers (including Pierre Fabre) of
such capacity and/or Raw Materials in the previous six month period; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> in no event shall Cypress and its sub-licensees receive
lesser quantities of API or less favorable delivery dates than the quantities and delivery dates then being allocated by Pierre Fabre to its own product(s). </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;MANUFACTURING AND SUPPLY WORKING GROUP.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1&nbsp;&nbsp;&nbsp;&nbsp;Establish the Working Group.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within 30&nbsp;days after the Effective Date, the parties will establish a
manufacturing and supply working group (the </FONT><FONT SIZE=2><B><I>"Working Group"</I></B></FONT><FONT SIZE=2>). The Working Group shall consist of six members, or such other even number of members as
agreed to by the parties, with an equal number of representatives on the Working Group appointed by each of Pierre Fabre and Cypress; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2>
Cypress may appoint one or more representatives of its sub-licensees as Cypress' representatives on the Working Group and, so long as Forest is a sub-licensee of Cypress under
the Restated License Agreement, one or more of the Cypress representatives on the Working Group shall be an employee of Forest (or of any Affiliate of Forest that is primarily responsible for the
activities of Forest under the Collaboration Agreement). Each member of the Working Group shall have experience appropriate for the activities to be conducted by the Working Group. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2&nbsp;&nbsp;&nbsp;&nbsp;Function of the Working Group.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The responsibilities of the Working Group are detailed on </FONT> <FONT
SIZE=2><B>Exhibit&nbsp;II</B></FONT><FONT SIZE=2>. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3&nbsp;&nbsp;&nbsp;&nbsp;Meetings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Prior to the first NDA filing for a Licensed Product, the Working Group shall meet on the dates mutually determined by
the Working Group. Following the date on which an NDA is filed for a Licensed Product, the Working Group shall meet at least one time each calendar quarter. Unless otherwise mutually agreed by the
parties, the location of the Working Group meetings shall alternate between Pierre Fabre's premises and Cypress' or its sub-licensees' premises or may be
held by telephone or video conference if requested by either party; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> after the first NDA filing for a Licensed Product, the Working Group
shall meet in person at least once a year. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The Working Group through one representative appointed by Cypress and one representative appointed by Pierre Fabre will
report its activities to the Steering Committee on a regular basis. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The Working Group may consult with, and receive assistance from each party's employees who are not Working Group members. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4&nbsp;&nbsp;&nbsp;&nbsp;Decision Making Authority.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre shall have final decision making authority with respect to those
activities identified on </FONT><FONT SIZE=2><B>Exhibit&nbsp;II</B></FONT><FONT SIZE=2> as responsibilities of Pierre Fabre and Cypress shall have final decision making authority with respect to
those activities identified on </FONT><FONT SIZE=2><B>Exhibit&nbsp;II</B></FONT><FONT SIZE=2> as responsibilities of Cypress; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> no
decision by either Pierre Fabre or Cypress shall conflict with applicable laws and regulations of the Licensed Territory, or the terms of the Restated License Agreement or this Agreement; and </FONT> <FONT SIZE=2><I>provided, further</I></FONT><FONT
SIZE=2>, that either party may refer any final decision by the other party to the chief officers of Pierre Fabre and Cypress. Such officers of
the parties shall meet </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=6,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=688925,FOLIO='6',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_7"> </A>

<P><FONT SIZE=2>promptly
thereafter and shall negotiate in good faith to resolve such issue within 30&nbsp;days of commencing such negotiations. </FONT></P>

<P><FONT SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>FORECASTS AND PURCHASE ORDERS.  </B></FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1&nbsp;&nbsp;&nbsp;&nbsp;Forecasts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the Term, Cypress and its sub-licensees shall follow the following forecast
and order procedures. </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;On the first business day of each calendar quarter during the period from the Effective Date until the first day of the
12<SUP>th</SUP> calendar month immediately preceding the calendar month during which the Estimated Date of First Commercial Sale is scheduled to occur, Cypress shall submit to Pierre Fabre a
Delivery Forecast for the </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period beginning on the first day of the calendar month immediately following the date of
submission of such Delivery Forecast. Each Delivery Forecast provided during this period shall provide quarterly forecasts for the applicable </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period. Such Delivery Forecast shall include
supplies of Bulk API required for formulation development and clinical
trials prior to the Estimated Date of First Commercial Sale. In addition, the Delivery Forecast submitted in January of each year during this
period shall also include a non-binding forecast for the </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period immediately following the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period covered by such Delivery Forecast.
Each Delivery Forecast submitted during this period will be a
non-binding estimate and shall not obligate Cypress or its sub-licensees to purchase any quantity of Bulk API, except that Cypress or its sub-licensees shall submit
to Pierre Fabre a binding purchase order no fewer than four months prior to any delivery date indicated by Cypress or its sub-licensees in a Delivery Forecast during this period. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Beginning on the first day of the 12<SUP>th</SUP> calendar month immediately preceding the calendar month during which
the Estimated Date of First Commercial Sale is scheduled to occur, and on the first day of each calendar month thereafter, Cypress shall submit to Pierre Fabre a rolling Delivery Forecast for the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT
SIZE=2> period beginning on the first day of the calendar month immediately following the date of submission of such
Delivery Forecast (e.g., submission on </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of a Delivery Forecast for the period from </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> through </FONT><FONT SIZE=2><B>[...***...]
</B></FONT><FONT SIZE=2>). Each Delivery Forecast
provided during this period shall provide monthly forecasts for the </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> and quarterly forecasts for the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the applicable </FONT><FONT
SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period. In
addition, the Delivery Forecast submitted in January of each year during this period shall also include a non-binding forecast for the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period immediately following the </FONT><FONT
SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>
period covered by such Delivery Forecast. Each Delivery Forecast submitted during this period will be a non-binding estimate and shall not obligate Cypress or its sub-licensees
to purchase any quantity of Bulk API, except as expressly provided below (an illustration of the following rules is provided in </FONT><FONT SIZE=2><B>Exhibit&nbsp;III</B></FONT><FONT SIZE=2>): </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of such Delivery Forecast shall
constitute a binding purchase order (</FONT><FONT SIZE=2><B><I>"Purchase Order"</I></B></FONT><FONT SIZE=2>) for both parties, meaning that Cypress and/or its sub-licensees agree to purchase and
Pierre Fabre agrees to supply the quantities of Bulk API indicated in the Purchase Order; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The quantities of Bulk API indicated in each of the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of such Delivery Forecast may reflect an increase or decrease of up to </FONT> <FONT
SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> compared to the quantity specified for the same calendar month in the immediately preceding Delivery Forecast; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The quantities of Bulk API indicated in each of the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> months of such Delivery Forecast may reflect an increase or decrease of up to </FONT>
<FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> compared to the quantity specified for the same calendar month in the immediately preceding Delivery Forecast;
 </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=7,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=618499,FOLIO='7',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_8"> </A>
<UL>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iv)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The quantities of Bulk API indicated in the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of such Delivery Forecast shall equal </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT
SIZE=2> of the aggregate quantities specified for the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period in the immediately preceding Delivery Forecast, plus or minus </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>; and
</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(v)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The quantities of Bulk API indicated in the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period of such Delivery Forecast shall be non-binding. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;&nbsp;&nbsp;Postponement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Prior to the calendar month during which the Estimated Date of First Commercial Sale is
scheduled to occur, Cypress may change the Estimated Date of First Commercial Sale, at no cost to Cypress, by notifying Pierre Fabre in writing. Thereafter, Cypress may postpone the Estimated Date of
First Commercial Sale one or more additional times (each, a </FONT><FONT SIZE=2><B><I>"Postponement"</I></B></FONT><FONT SIZE=2>) upon written notice to Pierre Fabre. In the event of a Postponement, other
than due to a delay by Pierre Fabre, Cypress or its sub-licensee shall be responsible for the costs of Bulk API ordered under any Purchase Order (whether such orders have been delivered by
Pierre Fabre or not) subject to the conditions set forth in Sections&nbsp;6 and 7.4, and Cypress and its sub-licensees shall have no other responsibility to Pierre Fabre as a result of
such Postponement. Pierre Fabre agrees that there shall be no limit on the number of Postponements or the duration of any Postponement that may be made by Cypress. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3&nbsp;&nbsp;&nbsp;&nbsp;Quantity of Orders.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties agree that forecasts and orders of Bulk API to be provided by Cypress will
be expressed by multiples of ten kilograms of Bulk API. </FONT></P>

<P><FONT SIZE=2><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>TRANSFER PRICE.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1&nbsp;&nbsp;&nbsp;&nbsp;Transfer Price.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;8.12, for Bulk API supplied by Pierre Fabre for commercial purposes, Cypress will pay to Pierre
Fabre a transfer price </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> per kilogram of Bulk API (as may be adjusted pursuant to Section&nbsp;5.1, the </FONT> <FONT SIZE=2><B><I>"Transfer Price"), </I></B></FONT><FONT SIZE=2>subject to the
terms of this Section&nbsp;5.1(a), which Transfer Price does not include tax: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;For Bulk API supplied by Pierre Fabre for formulation development of Licensed Product and all toxicology and
pharmacology studies and clinical trials of Licensed Product required for any NDA for Licensed Product, Cypress will pay </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of such Transfer Price; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;For Bulk API supplied by Pierre Fabre for Samples, so long as Forest has rights under the Licensed Technology, the
following provisions will apply: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(1)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Pierre Fabre will supply the following quantities of Bulk API for Samples </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>to Forest for the </FONT><FONT SIZE=2><B>[...***...]
</B></FONT><FONT SIZE=2> after the Date
of First Commercial Sale: (A)&nbsp;for the first year, </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>of the quantity of Bulk API supplied for Licensed Product
sold in such first year; (B)&nbsp;for the second year, </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the quantity of Bulk API supplied for Licensed Product
sold in such second year; and (C)&nbsp;for the third year, </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the quantity of Bulk API supplied for Licensed
Product sold in such third year. The foregoing quantities will be based on projected sales of Licensed Product for the applicable period, as reflected in the Sales Forecasts (as defined in the
Restated License Agreement) provided pursuant to Section&nbsp;5.3(a) of the Restated License Agreement, and reconciling payments with respect to Bulk API provided for Samples will be made by as
necessary within 60&nbsp;days after the end of the applicable year to reflect actual sales of Licensed Product in such year. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(2)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;For all quantities of Bulk API supplied by Pierre Fabre for Samples in excess of the quantities supplied under
Section&nbsp;5.1(a)(ii)(1) and throughout the Term, Pierre Fabre will supply such Bulk API at </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the Transfer
Price otherwise payable under this Section&nbsp;5.1(a), with Forest paying Pierre Fabre </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the Transfer Price
otherwise </FONT></P>

</UL>
</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=8,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=766881,FOLIO='8',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_9"> </A>
<UL>
<UL>
<UL>
<BR>

<P><FONT SIZE=2>payable
under this Section&nbsp;5.1(a) to supply such Bulk API, and Cypress paying Pierre Fabre </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the Transfer
Price otherwise payable under this Section&nbsp;5.1(a) to supply such Bulk API. </FONT></P>

</UL>

<P><FONT SIZE=2>Forest
shall maintain records regarding actual Sample distribution. Forest shall periodically provide to Pierre Fabre summaries of the information contained in such records and shall make such records
available to Pierre Fabre, at reasonable times and upon reasonable prior notice, at Pierre Fabre's request. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Transfer Price described in Section&nbsp;5.1(a) will be adjusted by Pierre Fabre on January&nbsp;1 of each year
during the Term, beginning on January&nbsp;1, 2004, according to the last published French index of consumer prices (Indice mensuel des prix &agrave; la consommation (base
100&#151;year 1998)&#151;Ensemble des M&eacute;nages France enti&egrave;re, as published in "Bulletin INSEE&#151;tableau 23.NE), or any successor thereto, the base
index being that of
January&nbsp;2003, i.e.: 106.9 (the </FONT><FONT SIZE=2><B><I>"Index"</I></B></FONT><FONT SIZE=2>); </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that in no event shall the Transfer
Price decrease or increase by more than </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> from the Transfer Price in effect for the prior calendar year.
Notwithstanding the foregoing, in the event any annual increase in the Index for a given calendar year exceeds </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>,
(i)&nbsp;the Transfer Price shall increase by </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> for the next calendar year, and (ii)&nbsp;if such </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>increase in such calendar year was
less than the actual percentage increase in Pierre Fabre's costs of manufacturing
Bulk API during that calendar year (as documented by Pierre Fabre to explain, in general terms, the basis for such actual percentage increase in costs of greater than </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>), then Pierre Fabre
shall have the right to apply the amount by which the actual percentage increase in Pierre
Fabre's costs of manufacturing Bulk API during such calendar year exceeds </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> (the </FONT> <FONT SIZE=2><I>"</I></FONT><FONT SIZE=2><B><I>Annual Excess</I></B></FONT><FONT
SIZE=2><I>"</I></FONT><FONT SIZE=2>), or any portion thereof, to a future adjustment in the Transfer Price for the first
year following such establishment of an Annual Excess that any such adjustment does not result in an increase in the Transfer Price in excess of </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> from that in effect for the prior year. Any
portion of an Annual Excess that is not used in the following year may
be carried over to subsequent years, and the unused portion of the Annual Excess for any and all years may be aggregated to be applied in determining an increase in the Transfer Price as provided
above. By way of illustration only, if the Index at January&nbsp;2004 and January&nbsp;2005 is 115.45 and 117.47, respectively, then (A)&nbsp;the Transfer Price for 2004 will be </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> and the
Annual Excess is </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> if the
actual percentage increase in Pierre Fabre's cost of manufacturing Bulk API was not less than the percentage increase in the Index, and (B)&nbsp;the Transfer Price for 2005 will be </FONT> <FONT SIZE=2><B>[...***...</B></FONT><FONT SIZE=2>]
</FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The Transfer Price is established on the Effective Date when the exchange rate is 1.15 U.S. Dollars to 1.00 Euros. In
connection with payment of the Transfer Price, if the exchange rate of U.S. Dollars to Euros, as reported in </FONT><FONT SIZE=2><I>The Wall Street Journal</I></FONT><FONT SIZE=2> (absent any error)
for the business day immediately preceding the applicable payment date is higher or lower than such exchange rate on the Effective Date by </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> or more, then Cypress or its sub-licensee, on the
one hand, and Pierre Fabre, on the other hand will
share equally the effect of the increase or decrease in such exchange rate to the extent of any increase or decrease of </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> or more over the exchange rate on the Effective Date (the </FONT><FONT
SIZE=2><B><I>"Shared
Amount"</I></B></FONT><FONT SIZE=2>), as provided below. The Shared Amount will be determined in respect of each payment of the Transfer Price. For any Shared Amount resulting from an increase in the
exchange rate of U.S. Dollars to Euros, Cypress or its sub-licensee shall be entitled to a payment from Pierre Fabre in an amount equal to </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of the Shared Amount. For any Shared Amount
resulting from a decrease in the exchange rate of U.S. Dollars to Euros,
Pierre Fabre shall be entitled to a payment from Cypress or its sub-licensee in an amount equal to </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of
the Shared Amount. Pierre Fabre shall determine and provide reasonable written evidence to Cypress of the net amount of all Shared Amounts for a given calendar year on or before January&nbsp;31 of
the following year, and the party owing such net amount shall promptly pay </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=9,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=260800,FOLIO='9',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_10"> </A>
<UL>

<P><FONT SIZE=2>such
net amount to the other party, absent manifest error in such information provided by Pierre Fabre. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2&nbsp;&nbsp;&nbsp;&nbsp;Payment Terms.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Payments pursuant to Section&nbsp;5.1 will be made by Cypress or its
sub-licensee to Pierre Fabre in Euros within 60&nbsp;days of the date of invoice. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3&nbsp;&nbsp;&nbsp;&nbsp;Late Payments.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that any payment due hereunder is not made when due, the payment shall accrue
interest from the date due at the rate of 1.5% per month; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that in no event shall such rate exceed the maximum legal annual interest
rate; </FONT><FONT SIZE=2><I>provided further</I></FONT><FONT SIZE=2> that no such interest shall accrue until the other party has provided written notice of such late payment or during any period
that any dispute with respect to a payment is being diligently pursued in good faith by the party from whom such payment is claimed. The payment of such interest shall not limit a party from
exercising any other rights it may have as a consequence of the lateness of any payment. </FONT></P>

<P><FONT SIZE=2><B>6.</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>DELIVERY.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to compliance with the forecast and order procedure set
forth in Section&nbsp;4, Pierre Fabre agrees to deliver Bulk API to Cypress or if designated by Cypress, its sub-licensee, in such quantities and on such monthly delivery dates as are
specified in Purchase Orders. With respect to orders not submitted in accordance with the forecast and order procedure, Pierre Fabre will use Commercially Reasonable Efforts to supply Cypress or its
sub-licensee with the quantities so ordered but shall have no obligation. Deliveries shall be made FCA French Airport (ICC Incoterms 2000) and shall be shipped to Cypress' address set
forth in this Agreement, or as otherwise directed by Cypress in writing. Bulk API delivered to Cypress or its sub-licensee shall be appropriately packaged by Pierre Fabre at its expense
for export shipment to the Licensed Territory. Delivery of Bulk API will be made by Pierre Fabre in conformity with a shipment protocol to be mutually agreed within the Working Group. </FONT></P>

<P><FONT SIZE=2><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>QUALITY ASSURANCE CONTROL&#151;ACCEPTANCE.  </B></FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1&nbsp;&nbsp;&nbsp;&nbsp;Minimum Time to Retesting API.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon delivery to Cypress or if designated by Cypress, its
sub-licensee, API will have a minimum time to retesting (the </FONT><FONT SIZE=2><B><I>"Minimum Time to Retesting"</I></B></FONT><FONT SIZE=2>) of </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> when the maximum time before retesting of
API is required, as authorized by the FDA
(</FONT><FONT SIZE=2><B><I>"Maximum Time Before Retesting"</I></B></FONT><FONT SIZE=2>) is </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>. In addition, Pierre Fabre
agrees to use Commercially Reasonable Efforts, including but not limited to conducting stability studies on API or enabling Cypress or its sub-licensee to conduct such studies, to obtain
FDA approval of an increase in the Maximum Time Before Retesting to </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>. Pierre Fabre shall provide Cypress with a
report of all data that Pierre Fabre obtains in such stability studies conducted by or on behalf of Pierre Fabre. In the event such increase in Maximum Time Before Retesting is approved by the FDA,
the Minimum Time to Retesting required upon delivery under this Section&nbsp;7.1 shall be increased to </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2&nbsp;&nbsp;&nbsp;&nbsp;Quality Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within 90&nbsp;days from the Effective Date, Cypress and Pierre Fabre will enter into a
Quality Agreement; </FONT><FONT SIZE=2><I>provided that,</I></FONT><FONT SIZE=2> if Cypress requests of Pierre Fabre in writing, Forest (or any
Affiliate of Forest that is primarily responsible for the activities of Forest under the Collaboration Agreement) may be added as a party to the Quality Agreement. Cypress and Pierre Fabre (and, if
applicable, Forest or any Affiliate of Forest that is primarily responsible for the activities of Forest under the Collaboration Agreement) shall amend the Quality Agreement from time to time as the
parties deem necessary. The Quality Agreement will include, at a minimum, the subject matter listed in </FONT><FONT SIZE=2><B>Exhibit&nbsp;IV</B></FONT><FONT SIZE=2>. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3&nbsp;&nbsp;&nbsp;&nbsp;Specifications; Testing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Batch Testing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre will perform standard analytical
testing of each manufactured batch to be delivered to Cypress hereunder to verify that it Conforms according to the procedure described in the corresponding documentation or as required by applicable
laws, regulation and authorities prior to shipment of each batch of Bulk API. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=10,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=468884,FOLIO='10',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_11"> </A>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Quality Control Sample.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Prior to delivery of any batch of
Bulk API, Pierre Fabre shall provide Cypress or its sub-licensee with (i)&nbsp;a quality control sample of such batch for the purpose of confirming that such batch Conforms, and
(ii)&nbsp;written confirmation that the corresponding batch record has been reviewed and approved by Pierre Fabre's Quality Assurance Department. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Quality Control Problem.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In addition, in the event Cypress,
its sub-licensee or Pierre Fabre identifies a quality problem with respect to a quality control sample or any batch sample of API, then, if requested by Cypress or its
sub-licensee in writing, Pierre Fabre shall authorize Cypress or its sub-licensee to consult at Pierre Fabre's facilities the full batch records corresponding to the applicable
quality control sample or applicable batch. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Certificate of Analysis.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre shall also provide a
certificate of analysis (the </FONT><FONT SIZE=2><B><I>"Certificate of Analysis"</I></B></FONT><FONT SIZE=2>) to Cypress or its sub-licensee with each shipment of Bulk API supplied hereunder.
Such Certificate of Analysis shall certify with respect to each shipment and batch (identified by batch number) (i)&nbsp;the quantity of the shipment, and (ii)&nbsp;that the Bulk API delivered
Conforms, as well as any further information required by the relevant regulatory authorities that Cypress may have previously notified Pierre Fabre is necessary. Cypress or its
sub-licensee shall be under no obligation to accept any shipment of Bulk API without an accompanying Certificate of Analysis. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4&nbsp;&nbsp;&nbsp;&nbsp;Acceptance and Rejection.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Acceptance of Quality Control Sample.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No delivery of Bulk
API shall be made until Cypress or its sub-licensee accepts or is deemed to have accepted the quality control sample of Bulk API, as provided in Section&nbsp;7.4(c) below.
Notwithstanding the above, the parties agree that if the delivery of one batch of Bulk API is made in several shipments and if Cypress or its sub-licensee has accepted the quality control
sample of such batch sent by Pierre Fabre before delivery of the first shipment, then Pierre Fabre shall not have any obligation to send a quality control sample of the same batch of Bulk API before
delivery of the shipments of the same batch. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Rejection.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cypress or its sub-licensee may
reject any quality control sample or batch delivery that does not Conform. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Quality Control Sample Testing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within 15&nbsp;days after
receipt of the applicable quality control sample, Cypress or its sub-licensee shall perform such samplings and tests that are designed, in accordance with the methods of analysis and API
specifications approved by the FDA, to determine whether the quality control sample Conforms. If Cypress or its sub-licensee rejects the quality control sample, Cypress or its
sub-licensee shall, within such 15&nbsp;day period, inform Pierre Fabre of its refusal to accept the quality control sample, and the reasons therefore; otherwise, Cypress or its
sub-licensee shall be deemed to have accepted the quality control sample and Pierre Fabre shall be entitled to deliver the corresponding batch (or portion thereof) of Bulk API to Cypress
or its sub-licensee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Replacement of Quality Control Sample.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon rejection by
Cypress or its sub-licensee of a quality control sample, within 10 business days of notice of such rejection, Pierre Fabre shall send a new quality control sample from a different API lot. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Bulk API Testing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within 30&nbsp;days of receipt of any
batch (or portion thereof) delivery of Bulk API at Cypress' facilities or such other destination as may be designated by Cypress, Cypress or its sub-licensee shall perform such samplings
and tests that are designed, in accordance with the methods of analysis and API specifications approved by the FDA, to determine whether the Bulk API Conforms. If Cypress or its
sub-licensee rejects any shipment of Bulk API, Cypress shall within such 30&nbsp;day period inform Pierre Fabre of its refusal to accept such shipment, and the reasons therefor;
otherwise, Cypress or its sub-licensee shall be deemed to have accepted said shipment; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> such acceptance shall not preclude a
subsequent rejection of any shipment </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=11,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=642322,FOLIO='11',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_12"> </A>
<UL>
<BR>

<P><FONT SIZE=2>of
Bulk API by Cypress or its sub-licensee following discovery of latent defects in such Bulk API (including, without limitation, discovery of any substance that would cause Bulk API to be
adulterated within the meaning of the FD&amp;C Act) that would not reasonably be detectable in accordance with industry standards in the Licensed Territory in the stated time period, provided that Cypress
or its sub-licensee notifies Pierre Fabre in writing within 30&nbsp;days of discovery of such latent defect. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Replacement of Bulk API and Dispute Procedure.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Following any
notice of rejection of Bulk API by Cypress or its sub-licensee, Pierre Fabre shall send a quality control sample within 10 business days of notice of rejection and furthermore, shall send
a replacement batch of Bulk API within 20 business days of approval by Cypress of such quality control sample. Pierre Fabre and Cypress and its sub-licensee shall investigate any failed
test result, in accordance with the procedure described in the Quality Agreement and as required by applicable cGMPs. As part of this investigation, Cypress and Pierre Fabre may mutually select an
independent laboratory to perform tests on representative samples from the rejected portion of the shipment and determine if it Conforms. The entire cost of such audit shall be paid by Pierre Fabre in
the event it is determined such Bulk API did not Conform, and by Cypress in the event it is determined that such Bulk API did Conform. The results of such tests shall be binding upon Cypress and
Pierre Fabre. The entire process described in this Section&nbsp;7.4(f), including any testing performed by an independent laboratory, shall be conducted diligently and within a maximum period of
180&nbsp;days from the date of notice of rejection by Cypress. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Cost of Replacement of Rejected Bulk API.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If it is
determined with or without reference to an independent laboratory that the rejected Bulk API did not Conform, the replacement batch shall be provided by Pierre Fabre at no other cost to Cypress than
the original price already paid for such non-Conforming Bulk API, with the same quantity of Bulk API which Conforms. Rejected Bulk API shall be returned to Pierre Fabre or disposed of at
Pierre Fabre's expense in accordance with Pierre Fabre's instructions, in which case Cypress shall deliver to Pierre Fabre an appropriate certificate of destruction. </FONT></P>

</UL>

<P><FONT SIZE=2><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>MANUFACTURE OF BULK API.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1&nbsp;&nbsp;&nbsp;&nbsp;Manufacture of Bulk API.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre will manufacture the Bulk API in accordance with the API
Specifications, cGMPs and other applicable rules and regulations of the FDA and other governmental or regulatory agencies within the Licensed Territory with jurisdiction over the manufacture, use or
sale of the API, as then in effect. The parties shall promptly notify each other of any new instructions or specifications required by the FDA, and of other applicable United States rules and
regulations. The parties shall confer with each other with respect to the best means to comply with such requirements and Pierre Fabre will bear the costs for implementing such changes. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2&nbsp;&nbsp;&nbsp;&nbsp;Multiple Suppliers.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre agrees that, beginning on the date of the first Purchase Order and
thereafter during the Term, it shall use Commercially Reasonable Efforts to have qualified more than one Pierre Fabre Supplier for each Starting Material. Furthermore, Pierre Fabre agrees that it
shall update Cypress through the Working Group of the number of Pierre Fabre Suppliers for each Raw Material, including Starting Materials. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3&nbsp;&nbsp;&nbsp;&nbsp;Changes to the API Specifications or to the Manufacturing Process.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre shall obtain the prior
written consent of Cypress (such consent not to be unreasonably withheld) with respect to any revisions to the API Specifications, and any change in the Raw Materials, equipment, process or procedures
used to manufacture the Bulk API (the </FONT><FONT SIZE=2><B><I>"Manufacturing Process"</I></B></FONT><FONT SIZE=2>) that would require pre-approval of the FDA or other applicable regulatory
authority of any country of the Licensed Territory (the </FONT><FONT SIZE=2><B><I>"Pre-Approved Changes"</I></B></FONT><FONT SIZE=2>). Pierre Fabre shall not require the consent of Cypress for
any revisions to the API Specifications, or the Manufacturing Process that would not require pre-approval </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=12,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=1044746,FOLIO='12',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_13"> </A>
<BR>

<P><FONT SIZE=2>of
the FDA or other applicable regulatory authority of any country of the Licensed Territory (</FONT><FONT SIZE=2><B><I>"Other Changes"</I></B></FONT><FONT SIZE=2>). Any changes to the API Specifications or
to the Manufacturing Process shall be in compliance with the NDA for Licensed Product and shall be implemented in accordance with a standard operating procedure to be later defined by the Working
Group. The corresponding costs of implementing any changes to the API Specifications or to the Manufacturing Process will be borne by Pierre Fabre. Pierre Fabre will inform the Working Group upon
implementation of any Pre-Approved Changes and shall discuss any proposed Pre-Approved Changes with the Working Group. Once the changes are effective, all references to the API
Specifications shall thereafter be deemed to refer to the API Specifications, as so modified, and all references to the Manufacturing Process, shall thereafter be deemed to refer to the Manufacturing
Process, as so modified. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4&nbsp;&nbsp;&nbsp;&nbsp;Cypress' Right to Audit Pierre Fabre Facility.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cypress and its sub-licensees shall have the
right, at their own expense, to conduct at mutually agreed times, but not more than twice a year, unless a major modification to the Manufacturing Process occurs or unless a quality problem has
arisen, quality control and quality assurance audits and/or inspection of Pierre Fabre's documentation and the facilities where Bulk API is manufactured (including, without limitation, a Second Source
Facility). Pierre Fabre will provide Cypress and its sub-licensees with reasonable access, during business hours upon reasonable prior notice, to Pierre Fabre's facilities where Bulk API
is manufactured, to review Pierre Fabre's manufacturing operations and assess its compliance with cGMPs and quality assurance standards and the opportunity to discuss any manufacturing issues with
Pierre Fabre's manufacturing and management personnel. Upon Cypress' written request, Pierre Fabre shall authorize Cypress or its sub-licensee to consult on site Pierre Fabre's
manufacturing records, including its master and production batch records, for the purposes of assuring product quality and compliance with the Quality Agreement and cGMPs. Cypress acknowledges that
all documentation relating to Pierre Fabre's manufacturing records shall be considered Confidential Information of Pierre Fabre and shall ensure that its sub-licensees are bound by at
least the same level of confidentiality obligations as contemplated by Section&nbsp;11.2. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5&nbsp;&nbsp;&nbsp;&nbsp;Compliance with Laws.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre shall comply with all applicable present and future orders, regulations,
requirements and laws of the Licensed Territory, and of local authorities and agencies of the Licensed Territory, as well as with all laws and regulations of other territories applicable to the
actions that it undertakes pursuant to this Agreement. Pierre Fabre represents and warrants to Cypress that it has and will maintain during the Term all government permits, including without
limitation health, safety and environmental permits, necessary for the conduct of the actions and procedures that it undertakes pursuant to this Agreement. Cypress shall provide Pierre Fabre with
written notice of any
additional regulatory requirements of countries of the Licensed Territory other than the United States of which Cypress is aware that relate to the manufacture of the Bulk API for such other
territories. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6&nbsp;&nbsp;&nbsp;&nbsp;FDA and Regulatory Support.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre agrees (i)&nbsp;to establish and maintain a Type II FDA Drug
Master File (</FONT><FONT SIZE=2><B><I>"DMF"</I></B></FONT><FONT SIZE=2>) in accordance with the requirements of the FDA, as well as any comparable files required by regulatory authorities in other
countries within the Licensed Territory, (ii)&nbsp;to provide Cypress and its sub-licensees with letters of access to the DMF and any other comparable files and (iii)&nbsp;to further
provide Cypress and its sub-licensees with all necessary information and data regarding the manufacture of Bulk API to the extent necessary for Cypress and its sub-licensees to
prepare and defend any inquiries from the FDA or to exercise the Manufacturing Right set forth in Section&nbsp;8.11, to satisfy regulatory requirements in the Licensed Territory. Pierre Fabre
further agrees to use Commercially Reasonable Efforts to assist Cypress and its sub-licensees in obtaining FDA approval for its NDA with respect to the Licensed Product, as well as
approvals from any other government or agency which may be required for the marketing of the Licensed Product in any other country within the Licensed Territory. Pierre Fabre specifically agrees to
cooperate with any inspection by the FDA or other regulatory agency, including but not limited to any inspection prior to </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=13,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=851741,FOLIO='13',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_14"> </A>
<BR>

<P><FONT SIZE=2>approval
of Cypress' NDA for the Licensed Product. Pierre Fabre shall notify Cypress and its sub-licensees of which Pierre Fabre is aware within two business days of any FDA inspection
relating to API or any API related facility and, at the conclusion of such inspection, shall be promptly furnished with a copy of all documentation, including any Form&nbsp;483 and Pierre Fabre
response thereto, relating to such inspection. In addition, Pierre Fabre shall promptly notify Cypress and its sub-licensees of any other regulatory actions or communications (other than
ministerial, non-substantive communications) relating to API or any API related facility. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7&nbsp;&nbsp;&nbsp;&nbsp;Documentation.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre shall keep complete, accurate and authentic accounts, notes, data and records of
the work performed under this Agreement. Each party shall maintain complete and adequate records pertaining to the methods and facilities used for the manufacture, processing, testing, packing,
labeling, holding and distribution of the Bulk API in accordance with the applicable regulations in the Licensed Territory so that the Bulk API may be used in the production of the Licensed Product,
which shall be used in humans. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8&nbsp;&nbsp;&nbsp;&nbsp;Reprocessing and Reworking of Bulk API.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre agrees that any reprocessing or reworking of any batch
or lot of Bulk API shall be made in full compliance with the procedures described in the DMF, or, if not made in compliance with the procedures described in the DMF, Pierre Fabre shall obtain the
prior written consent of Cypress, which consent shall not be unreasonably withheld. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.9&nbsp;&nbsp;&nbsp;&nbsp;Buffer Stock.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Requirement of Pierre Fabre Buffer Stock.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Beginning on the
date that is </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> and thereafter during the Term, Pierre Fabre shall have available (including as a result of API
manufactured by any Second Source Facility) a buffer stock of API (the </FONT><FONT SIZE=2><B><I>"Buffer Stock"</I></B></FONT><FONT SIZE=2>), as determined by the Working Group on at least an annual basis,
with the initial determination to be made no later than June&nbsp;30, 2004, subject to Section&nbsp;8.9(b). In establishing the level of the Buffer Stock, the Working Group may consider the API
and Licensed Product inventory levels that will be maintained by Cypress and its sub-licensees. The level of Buffer Stock will be expressed as a number of months of supply of API and will
be determined based upon the quantities specified in the most recent applicable months of the Delivery Forecast (including Purchase Orders). For example, if the level of Buffer Stock is a </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>
supply, then the Buffer Stock will be an amount of API equal to the quantities of API specified in the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of then most recent Delivery Forecast, including the </FONT> <FONT SIZE=2><B>[...***...]
</B></FONT><FONT SIZE=2>that constitute Purchase Orders and the </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> immediately following such </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2>.
 </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Maximum and Minimum Buffer Stock.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Buffer Stock
determined by the Working Group (i)&nbsp;shall not exceed (A)&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of API, if there is only one manufacturing
facility available for the manufacture of API by or for Pierre Fabre or (B)&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of API if there is more than one
manufacturing facility available for the manufacture of API by or for Pierre Fabre, unless agreed in writing by Pierre Fabre; and (ii)&nbsp;shall not be less than
(x)&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of API at any time there is only one manufacturing facility available for the manufacture of API by or
for Pierre Fabre, or (y)&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> of API at any time there is more than one manufacturing facility available for the
manufacture of API by or for Pierre Fabre (the </FONT><FONT SIZE=2><B><I>"Minimum Buffer Stock"</I></B></FONT><FONT SIZE=2>). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Information on Buffer Stock; Depletion.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each month, within
seven days after receipt of the applicable Delivery Forecast, Pierre Fabre will calculate the amount of Buffer Stock based on the latest Delivery Forecast and will compare it to the actual current
Buffer Stock (the "</FONT><FONT SIZE=2><B><I>Current Buffer Stock</I></B></FONT><FONT SIZE=2>"). Pierre Fabre will provide Cypress and its sub-licensees with information regarding the Current
Buffer Stock from time to time. In the event that, at any time, the Current Buffer Stock is less than the Minimum Buffer Stock (a "</FONT><FONT SIZE=2><B><I>Shortfall</I></B></FONT><FONT SIZE=2>"), then
Pierre Fabre shall, within 15 business days of the discovery of the Shortfall, provide written notice to Cypress of such Shortfall and a written, commercially reasonable plan detailing its plans to
address any problems or issues </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=14,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=102004,FOLIO='14',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<A NAME="page_lr1113_1_15"> </A>
<UL>
<BR>

<P><FONT SIZE=2>contributing
to such Shortfall (a </FONT><FONT SIZE=2><B><I>"Correction Plan"</I></B></FONT><FONT SIZE=2>). If Pierre Fabre provides Cypress a Correction Plan within such 15 business days, Pierre Fabre
shall have a period following the date on which such Shortfall occurred to increase the level of the Current Buffer Stock to at least the Minimum Buffer Stock as follows: (i)&nbsp;a </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period
if there is then only one manufacturing facility available for the manufacture of API, or (ii)&nbsp;a </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period if there is then more than one manufacturing facility available for the
manufacture of API. If Pierre Fabre
does not increase the level of the Current Buffer Stock to at least the Minimum Buffer Stock within the </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> or </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> period, as applicable,
or notifies Cypress that it reasonably believes in good faith that it will be unable to cure
the Shortfall within such applicable period, or Pierre Fabre does not provide a Correction Plan within the 15 business day period described above, Cypress shall have the right, immediately upon notice
to Pierre Fabre, to exercise the Manufacturing Right under Section&nbsp;8.11. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Cost of Carrying Buffer Stock; Audit.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The cost of carrying
the Buffer Stock and insuring the same shall be borne by Pierre Fabre. The cost of carrying an inventory of API and Licensed Product maintained by Cypress or its sub-licensees and insuring
the same shall be borne by Cypress or its sub-licensees. Beginning three months after Date of First Commercial Sale, Cypress and its sub-licensees shall have the right to audit
the API inventory levels of Pierre Fabre and the Second Source Facility, if applicable, to verify Pierre Fabre's compliance with this Section&nbsp;8.9, and Pierre Fabre shall have the right to audit
the API inventory levels of Cypress and its sub-licensees, which audits shall be conducted at the auditing party's expense, at reasonable times and upon reasonable advance written notice. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.10&nbsp;&nbsp;&nbsp;&nbsp;Second Source Facility.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No later than </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> and
thereafter during the Term, Pierre Fabre shall have qualified and keep qualified an additional manufacturing
facility (a </FONT><FONT SIZE=2><B><I>"Second Source Facility"</I></B></FONT><FONT SIZE=2>), in addition to the facility located in Gaillac, France, for the production of API to ensure a second source of
supply of API to Cypress. The Second Source Facility must be a second facility operated by Pierre Fabre or any licensee or subcontractor of Pierre Fabre with quality and reliability in manufacturing
comparable to Pierre Fabre's first facility, and such Second Source Facility must be approved by the FDA or other relevant regulatory authorities for the countries of the Licensed Territory such that
the Licensed Products containing API manufactured by the Second Source Facility may be lawfully sold by Cypress. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.11&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing Rights.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Qualification.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At any time during the Term, Cypress shall
have the right, but not the obligation, to qualify itself or one of its sub-licensees as an additional manufacturing facility that may undertake the manufacture of Bulk API, but may not
exercise the right to manufacture except as expressly provided in Section&nbsp;8.11(b). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Manufacturing Right.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Without limiting any other right of
Cypress under this Agreement, Cypress shall have the right, but not the obligation, to make itself, or have made by any Third Party, API in order to satisfy Cypress' and its sub-licensees'
requirements of Bulk API (the "</FONT><FONT SIZE=2><B><I>Manufacturing Right</I></B></FONT><FONT SIZE=2>"), all pursuant to the license granted under Section&nbsp;8.11(d), if one of the following events
occurs: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If Cypress exercises its rights in respect of a Shortfall pursuant to Section&nbsp;8.9(c); or </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If Cypress terminates the Restated License Agreement pursuant to Section&nbsp;14.2(a)(i)&nbsp;or (ii)&nbsp;thereof
or under the circumstances described in Section&nbsp;10.3(e) of this Agreement. </FONT></P>

</UL>

<P><FONT SIZE=2>In
the event Cypress or its sub-licensee wishes to exercise the Manufacturing Right, Cypress shall provide Pierre Fabre with written notice thereof no fewer than 30&nbsp;days in advance
of the effective date of such exercise (the </FONT><FONT SIZE=2><B><I>"Exercise Date"</I></B></FONT><FONT SIZE=2>). </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=10,SEQ=15,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=849912,FOLIO='15',FILE='DISK043:[04SAN3.04SAN1113]LR1113A.;8',USER='JMAHER',CD='28-MAR-2004;18:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_ls1113_1_16"> </A> </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Duration of Manufacturing Right.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;It is agreed by the parties
that: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If Cypress has exercised the Manufacturing Right under Section&nbsp;8.11(b)(i), the Manufacturing Right shall continue
until Pierre Fabre has resumed and restored its capability to manufacture and supply Cypress' and its sub-licensees' requirements of Bulk API and recommences its manufacture and supply of
Bulk API, or if longer, for the duration of any commercially reasonable obligation to any Third Party supplier entered into in connection with the exercise of the Manufacturing Right. If Cypress and
its sub-licensees continue to have obligations to any Third Party supplier entered into in connection with the exercise of the Manufacturing Right after Pierre Fabre has resumed its
capability to manufacture and supply under this Agreement, Cypress and its sub-licensees will purchase such portion, if any, of their requirements of Bulk API from Pierre Fabre pursuant to
this Agreement as can be purchased given the obligations to such Third Party supplier. When assessing Third Party suppliers in connection with the exercise of the Manufacturing Right, Cypress will
consider any Third Party suppliers suggested by Pierre Fabre and will in good faith attempt to select a Third Party supplier that will permit Pierre Fabre to resume manufacture and supply under this
Agreement as promptly as possible after it is able to do so, subject to commercially reasonable considerations of material differences in qualification, reliability, pricing, quality and other similar
factors, considered as a whole, with respect to such potential Third Party suppliers. Pierre Fabre shall provide Cypress with written notice of its ability to recommence manufacturing and supplying
Cypress and its sub-licensees with their requirements of Bulk API no less than </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> months in advance. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If Cypress has exercised the Manufacturing Right under Section&nbsp;8.11(b)(ii), then the Manufacturing Right shall be
perpetual. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>License Grant.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Effective upon the Exercise Date, Pierre
Fabre hereby grants to Cypress a worldwide, non-exclusive, </FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> license, with the right to
sub-license, under the Licensed Technology and the Manufacturing Know-How to make and have made API. Such license shall continue so long as the Manufacturing Right continues to
be in effect under Section&nbsp;8.11(c). In the event a license is granted to Cypress by Pierre Fabre under this Section&nbsp;8.11(d), Pierre Fabre shall promptly transfer to Cypress or its
sub-licensee such Licensed Technology and Manufacturing Know-How and any other Information and data concerning and related to the manufacture and supply of Bulk API and shall
assist Cypress and any sub-licensee of Cypress in the implementation thereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Provision of Information.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event the Manufacturing
Right is exercised, Pierre Fabre shall provide Cypress (without cost to Cypress, except as provided in Section&nbsp;10.3(e), if applicable) all reasonable relevant Information, data and
Manufacturing Know-How necessary or useful
for Cypress to qualify an alternative facility or to manufacture Bulk API, as applicable. In such event, Pierre Fabre also agrees to send to the location designated by Cypress such specialized
technical and scientific personnel as Pierre Fabre deems necessary for a maximum of two stays, each stay not to exceed two weeks to assist in the technical aspects of the manufacturing of the Bulk
API. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Reimbursement of Costs.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Without limiting any other right of
Cypress under this Agreement, upon the Exercise Date if the Manufacturing Right is exercised pursuant to Section&nbsp;8.11(b)(i), Pierre Fabre agrees to reimburse Cypress for all reasonable and
documented out-of-pocket costs incurred by Cypress and, if applicable, its sub-licensees, in exercising the Manufacturing Right, including, without limitation,
documented costs incurred for transferring the Manufacturing Know-How, laboratory trials, and writing and filing of a DMF. The amounts owed by Pierre Fabre for reimbursement of such costs
will be fully credited against earned royalties due by Cypress to Pierre Fabre under Section&nbsp;6.4 of the Restated License Agreement. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=16,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=898884,FOLIO='16',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_17"> </A>
<UL>
<BR>
</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.12&nbsp;&nbsp;&nbsp;&nbsp;Third Party Outsourcing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On a country by country basis, Pierre Fabre shall remain the exclusive supplier of
API to Cypress and its sub-licensees, until commercial launch of a Generic Product in such country, subject to the terms of this Agreement. In the event of commercial launch of a Generic
Product, including, without limitation, any planned launch of a Generic Product by Cypress or its sub-licensee(s), in a country of the Licensed Territory, then Pierre Fabre will remain
exclusive supplier of the API to Cypress and its sub-licensees for such country, as long as Pierre Fabre can supply API to Cypress and its sub-licensee(s), including, without
limitation, any quantities of API for Generic Product for commercial launch in the event Cypress or its sub-licensee(s) launch the first Generic Product, at a price no greater than </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> above the
price quoted by a Third Party generic supplier (a </FONT><FONT SIZE=2><B><I>"Generic
Supplier"</I></B></FONT><FONT SIZE=2>) for API that Conforms. Cypress may, from time to time, provide notice to Pierre Fabre of its or its sub-licensee's intent to purchase API from a Generic
Supplier (the "</FONT><FONT SIZE=2><B><I>Outsourcing Notice</I></B></FONT><FONT SIZE=2>"), together with documentation evidencing the lower price for the API that Conforms to be supplied by such Generic
Supplier for such country; </FONT><FONT SIZE=2><I>provided, that:</I></FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;if, within 30&nbsp;days following Pierre Fabre's receipt of the Outsourcing Notice, Pierre Fabre has not provided
written notice to Cypress indicating its agreement to lower the price of the API for the applicable country to a level not exceeding </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> above the price quoted by the Generic Supplier, then,
Cypress may notify Pierre Fabre its decision to terminate the
obligation to purchase all API requirements for such country from Pierre Fabre under this Agreement, as provided in Section&nbsp;10.2(b). Upon receipt of said notice by Pierre Fabre, Cypress may
terminate this Agreement with respect to such country under Section&nbsp;10.2(b); and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;if, within 30&nbsp;days following Pierre Fabre's receipt of the Outsourcing Notice, Pierre Fabre has provided written
notice to Cypress lowering the price of the API for the quantity in the applicable country so that the Transfer Price of API for such quantity and such country is no greater than </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> above the
price quoted by the Generic Supplier, then Cypress
will remain obligated to purchase API from Pierre Fabre in accordance with the provisions of this Agreement. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.13&nbsp;&nbsp;&nbsp;&nbsp;Recall of Licensed Product.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For any Licensed Product, in the event that (i)&nbsp;any governmental agency
or authority issues a request or directive or order that Licensed Product be recalled or retrieved; (ii)&nbsp;a court of competent jurisdiction orders that Licensed Product be recalled or retrieved;
or (iii)&nbsp;Cypress or any of its sub-licensees reasonably determines, after reasonable, good faith discussion with Pierre Fabre, that Licensed Product should be recalled or retrieved,
Cypress shall promptly notify Pierre Fabre of such event and shall conduct such activity and take appropriate corrective actions, and Pierre Fabre shall provide such assistance to Cypress and its
sub-licensees as is reasonably necessary to carry out such activities. All reasonable costs and expenses of such recall and corrective actions shall be the responsibility of Cypress or its
sub-licensees, </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> Pierre Fabre shall indemnify Cypress and its sub-licensees for such cost and expense in accordance
with Section&nbsp;9.2 below. </FONT></P>

<P><FONT SIZE=2><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>WARRANTIES, INDEMNITIES AND ADDITIONAL COVENANTS.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1&nbsp;&nbsp;&nbsp;&nbsp;Product Warranty.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre warrants that API delivered hereunder will:&nbsp;(a)&nbsp;Conform at the
time of delivery; (b)&nbsp;be manufactured by Pierre Fabre in accordance with cGMP and other applicable FDA and other laws, rules and regulations of the United States and as applicable, the other
countries in the Licensed Territory; (c)&nbsp;have the Minimum Time to Retesting; and (d)&nbsp;not be adulterated or misbranded within the meaning of the FD&amp;C Act. The parties acknowledge that
Pierre Fabre will be responsible for the stability of the Bulk API for the shelf life indicated in the API Specifications, subject to Cypress evidencing that, during its total shelf life,
transportation, storage and use of the Bulk API have been made in accordance with Pierre Fabre's instructions. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=17,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=334979,FOLIO='17',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_18"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Cypress Indemnification.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cypress hereby agrees to save,
defend, indemnify and hold harmless Pierre Fabre and its shareholders, officers, directors, employees, consultants and agents (</FONT><FONT SIZE=2><B><I>"Pierre Fabre
Indemnitees"</I></B></FONT><FONT SIZE=2>) from and against, and to pay on behalf of or reimburse such Pierre Fabre Indemnitees for, any and all losses, damages, liabilities, expenses and costs, whether
based on products liability or otherwise, including, but not limited to, court costs and reasonable attorneys' fees and expenses (collectively,
"</FONT><FONT SIZE=2><B><I>Losses</I></B></FONT><FONT SIZE=2>"), to which any Pierre Fabre Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (an </FONT> <FONT
SIZE=2><B><I>"Action"</I></B></FONT><FONT SIZE=2>) to the extent such Losses
arise directly out of (i)&nbsp;the material breach by Cypress of any representation or warranty under this Agreement, or (ii)&nbsp;the development, manufacture, use, handling and storage, sale or
other disposition of any Licensed Product by Cypress, its Affiliates and sub-licensees, except to the extent such Losses result from the negligence or willful misconduct of any Pierre
Fabre Indemnitee or are Losses for which Pierre Fabre is obligated to indemnify any Cypress Indemnitee under Section&nbsp;9.2(b). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Pierre Fabre Indemnification.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre hereby agrees to
save, defend, indemnify and hold harmless Cypress and its sub-licensees and their respective shareholders, officers, directors, employees, consultants and agents
(</FONT><FONT SIZE=2><B><I>"Cypress Indemnitees"</I></B></FONT><FONT SIZE=2>) from and against, and to pay on behalf of or reimburse such Cypress Indemnitees for, any and all Losses to which any Cypress
Indemnitee may become subject as a result of any Action to the extent such Losses arise directly out of (i)&nbsp;the material breach by Pierre Fabre of any representation or warranty under this
Agreement, (ii)&nbsp;the manufacture, use, handling and storage of API by Pierre Fabre, its Affiliates, licensees and sub-contractors (other than Cypress or its
sub-licensees), except to the extent such Losses result from the negligence or willful misconduct of any Cypress Indemnitee or are Losses for which Cypress is obligated to indemnify any
Pierre Fabre Indemnitee under Section&nbsp;9.2(a) or (iii)&nbsp;to the extent that the recall and corrective actions taken under Section&nbsp;8.13 are caused by (x)&nbsp;any breach by Pierre
Fabre of its obligations or representations under this Agreement, or (y)&nbsp;any intentional or negligent act or omission of Pierre Fabre or its Affiliates or any of their directors, officers,
employees or agents in connection with the manufacture and supply of API. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Limitation of Liability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in
Section&nbsp;11.2, neither party makes any other warranties express or implied, except as set forth herein and neither party shall be liable to the other party for special consequential or
incidental damages in connection with this Agreement or any license granted hereunder. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3&nbsp;&nbsp;&nbsp;&nbsp;Control of Defense.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The party seeking indemnification under Section&nbsp;9.2 (the </FONT><FONT SIZE=2><B><I>"Indemnified
Party"</I></B></FONT><FONT SIZE=2>), agrees to give notice to the party providing such indemnification (the "</FONT><FONT SIZE=2><B><I>Indemnifying Party</I></B></FONT><FONT SIZE=2>") of the assertion of any
claim, or commencement of any Action in respect of which indemnity may be sought under Section&nbsp;9.2 promptly after receipt of notice from a Third Party of the assertion or commencement of such
Action. Failure to notify the Indemnifying Party shall not relieve the Indemnifying Party of any liability that the Indemnifying Party might have to the Indemnified Party unless and to the extent such
failure can be demonstrated to have materially prejudiced the Indemnifying Party's position. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The Indemnifying Party shall be entitled, at its own expense, to participate in or, to the extent that it desires, to
assume the defense of any such Action with its own counsel. If the Indemnifying Party elects to assume such defense, it shall select counsel for the Indemnified Party, which may be the same counsel as
for the Indemnifying Party, at the Indemnifying Party's expense, subject to the limitations set forth below in this Section&nbsp;9.3. In such a case, the Indemnified Party shall not be entitled to
reimbursement for the costs of its own counsel. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=18,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=13129,FOLIO='18',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_19"> </A>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;The Indemnifying Party shall not be entitled to assume the defense of an Action (unless otherwise agreed to in writing by
the Indemnified Party) and shall pay the fees and expenses of counsel reasonably acceptable to the Indemnifying Party retained by the Indemnified Party if (1)&nbsp;the claim for indemnification
relates to or arises in connection with any criminal or quasi-criminal proceeding, action, indictment, allegation or investigation; or (2)&nbsp;the Indemnified Party has been advised by counsel
reasonably acceptable to the Indemnifying Party that a reasonable likelihood exists of a conflict of interest between the Indemnifying Party and the Indemnified Party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Even if the Indemnifying Party has assumed control of the defense for an Indemnified Party, the Indemnified Party shall
be entitled to participate in the defense of an Action and to employ counsel of its choice for such purpose; </FONT><FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> the fees and expenses of such
separate counsel shall be borne by the Indemnified Party (other than any fees and expenses of such separate counsel that are incurred prior to the date the Indemnifying Party effectively assumes
control of such defense which, notwithstanding the foregoing, shall be borne by the Indemnifying Party, and except that the Indemnifying Party shall pay all of the fees and expenses of such separate
counsel under the circumstances outlined in Section&nbsp;9.3(c) above). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Each party agrees to cooperate to the fullest extent possible as requested by the other in the defense of the claim
arising out of an Action, with out-of-pocket expenses resulting from any such cooperation to be at the expense of the Indemnifying Party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Indemnifying Party shall control the defense of an Action, the Indemnifying Party shall obtain the prior written
consent of the Indemnified Party before entering into any settlement of a claim or ceasing to defend such claim if, pursuant to or as a result of such settlement or cessation, injunctive or other
equitable relief will be imposed against the Indemnified Party or if such settlement does not expressly and unconditionally release the Indemnified Party from all liabilities and obligations with
respect to such claim, without prejudice. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, to the extent that an Indemnified Party receives insurance
proceeds as a result of any Loss, the Indemnified Party shall pay the amount of such insurance proceeds (but not in excess of the indemnification payment or payments actually received
from the Indemnifying Party with respect to such Loss) to the Indemnifying Party promptly after such insurance proceeds are actually received by the Indemnified Party. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;During the Term, Pierre Fabre, at its own expense, shall maintain product liability insurance (or self insure) in an
amount consistent with industry standards for claims and actions that might be taken against it in connection with this Agreement. At the request of Cypress, Pierre Fabre shall provide a certificate
of insurance (or evidence of self insurance) evidencing such coverage. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;During the Term, Cypress, at its own expense, shall maintain, and shall cause its sub-licensees to maintain,
product liability insurance (or self-insure) in amount consistent with industry standards for claims and actions that might be taken against it in connection with this Agreement. At the
request of Pierre Fabre, Cypress shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=19,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=885690,FOLIO='19',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_20"> </A>
<UL>
<BR>
</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5&nbsp;&nbsp;&nbsp;&nbsp;Mutual Representations and Warranties.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each party represents and warrants to the other that, as of the
Effective Date: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Power.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;It is duly organized and validly existing under the
laws of its jurisdiction of incorporation or formation, and has full power and authority to enter into this Agreement and to carry out the provisions hereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Due Authorization.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;It is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has or have been duly authorized to do so by all requisite action. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Binding Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is legally binding upon
it, enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Grant of Rights; Maintenance of Agreements.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;It has not, and
will not during the Term, grant any right to any Third Party that would conflict with the rights granted to the other party hereunder. It has (or will have at the time performance is due) maintained
and will maintain and keep in full force and effect all agreements (including license agreements) and filings (including patent filings) necessary to perform its obligations hereunder. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre Representations and Warranties.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre represents and warrants to Cypress that, as of the
Effective Date: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Ownership of Licensed Technology and Manufacturing
Know-How.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre owns or otherwise has adequate rights to the Licensed Technology and the Manufacturing Know-How and has the right to
perform its obligations under this Agreement and such obligations do not conflict with or violate the terms of any agreement between Pierre Fabre and any Third Party. It owes no royalties or other
obligations to any Third Party (including, without limitation, officers, directors, employees or other consultants or agents of Pierre Fabre), in connection with its rights to the Licensed Technology,
and such rights are not subject to termination or limitation by any Third Party. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Notice of Proceedings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre has informed Cypress
that to its knowledge, there is no administrative or judicial proceedings contesting the inventorship, ownership, validity or enforceability of any element of the Licensed Technology or the
Manufacturing Know-How nor is Pierre Fabre aware of any reasonable basis for such proceeding or claim. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Patent Infringement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, (i)&nbsp;to
Pierre Fabre's knowledge, the practice of the Licensed Technology to develop or commercialize Licensed Product and the practice of the Manufacturing Know-How to manufacture API and Bulk
API does not infringe any patents of any Third Party, and (ii)&nbsp;Pierre Fabre has not received any written notice or communication alleging that the practice of the Pierre Fabre Patents infringes
or may infringe any patent of any Third Party or alleging that the practice of the Manufacturing Know-How infringes or may infringe any intellectual property rights of any Third Party nor
is Pierre Fabre aware of any reasonable basis for such proceeding or claim. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre Covenant.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre has disclosed to Cypress all Pierre Fabre Know-How requested
by Cypress and to the extent required under this Agreement, the Manufacturing Know-How, requested by Cypress and will continue after the Effective Date to disclose and provide to Cypress,
all Confidential Information and data in the possession of Pierre Fabre or its Affiliates which is reasonably necessary for Cypress or its sub-licensees to prepare and defend to any
inquiries from the FDA or other relevant authorities in any country of the Licensed Territory. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=20,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=1018711,FOLIO='20',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_21"> </A>

<P><FONT SIZE=2><B>10.&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>TERM; TERMINATION.  </B></FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1&nbsp;&nbsp;&nbsp;&nbsp;Term.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The term of this Agreement shall commence on the Effective Date and continue for a period of
10&nbsp;years from the First Commercial Sale of the Licensed Product by Cypress, its Affiliates and/or sub-licensees in the Licensed Territory, unless sooner terminated in accordance
with Section&nbsp;10.2 (the </FONT><FONT SIZE=2><B><I>"Term"</I></B></FONT><FONT SIZE=2>). Twelve months prior to the expiration of the Term, Cypress and Pierre Fabre will mutually decide whether or not
the supply relationship should be extended and if the parties mutually agree to extend such supply relationship, the parties shall attempt to agree on the terms of such supply relationship. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2&nbsp;&nbsp;&nbsp;&nbsp;Early Termination.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Termination for Cause by Either Party.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A party shall have
the right to terminate this Agreement upon 90&nbsp;days' prior written notice to the other upon the occurrence of any of the following: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Upon or after the bankruptcy, insolvency, dissolution or winding up of the other party (other than a dissolution or
winding up for the purpose of reconstruction or amalgamation); or if a party admits in writing its inability to pay its debts as they become due, or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Upon or after the breach of any material provision of this Agreement by the other party
(</FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that the existence of a Shortfall and the exercise of the Manufacturing Right in connection therewith shall not constitute a breach of a
material provision of this Agreement by Pierre Fabre so long as Pierre Fabre complies with its obligations under Section&nbsp;8.11) if the breaching party has not cured such breach within the
90&nbsp;day (30&nbsp;day in the event of a breach of Section&nbsp;6) period following written notice of termination by the non-breaching party, or, if such breach (excluding any
breach of Section&nbsp;6) is not susceptible of cure within such 90&nbsp;day period, the breaching party has not taken appropriate steps to cure during such 90&nbsp;day period and continued to
diligently pursue such cure in a manner reasonably assuring such cure within a reasonable period of time thereafter. In addition, termination shall not be permitted for a payment breach where the
obligation to make payment is being diligently contested in good faith by appropriate proceedings and any required payment is promptly made following completion of dispute resolution as contemplated
hereby. In any event, if any such breach has not been cured within one year of the date of occurrence of the breach, the non-breaching party may terminate this Agreement under this
Section. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Termination by Cypress.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cypress may terminate its rights and
obligations under this Agreement with respect to the applicable country, if within 30&nbsp;days following receipt of an Outsourcing Notice sent by
Cypress pursuant to Section&nbsp;8.12, Pierre Fabre has not provided written notice to Cypress agreeing to lower the price of the API to a level not exceeding </FONT> <FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2> above the price quoted by a
Generic Supplier. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Termination by Pierre Fabre.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre may terminate this
Agreement as provided in Section&nbsp;11.8(b). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B>Termination of the Restated License Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall automatically terminate upon early termination of the Restated License Agreement by Pierre Fabre pursuant to Sections 14.2(a) or 14.2(b) of the Restated License Agreement. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3&nbsp;&nbsp;&nbsp;&nbsp;Effect of Expiration; Termination; Surviving Obligations.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Upon early termination of this Agreement by Cypress pursuant to Section&nbsp;10.2(a), in addition to the provisions set
forth in Section&nbsp;10.3(c), Sections 8.11(b), 8.11(c), 8.11(d) and 8.11(e) shall survive such termination. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=21,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=135425,FOLIO='21',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_22"> </A>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Upon early termination of this Agreement by Pierre Fabre pursuant to Section&nbsp;10.2(a) or 10.2(d), then: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;all rights granted to Cypress hereunder shall terminate, and, subject to Section&nbsp;10.3(d), Cypress and its
affiliates and sub-licensees shall cease all use of such Manufacturing Know-How and shall comply with the provisions of Section&nbsp;11.2 with respect to Pierre Fabre's
Confidential Information; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Restated License Agreement shall automatically terminate with the consequences described in
Section&nbsp;14.3(b)(ii)&nbsp;of the Restated License Agreement. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Expiration or early termination of this Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the parties under Sections 9.2. "Indemnification", 9.3 "Control of Defense", 10.3
"Effect of Expiration; Termination; Surviving Obligations", 10.4 "Exercise of Right to
Terminate", 10.5 "Damages; Relief", 11.1 "Dispute Resolution and Arbitration", 11.2 "Confidentiality" and 11.3 "Governing Law and Venue" shall survive expiration or termination of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;Upon early termination of this Agreement under Section&nbsp;10.2(d) as a result of early termination of the Restated
License Agreement by Pierre Fabre pursuant to Section&nbsp;14.2(a)(i), this Agreement shall survive as to any sub-licensee under a sub-license granted Cypress under the
License Agreement that survives and becomes a direct license from Pierre Fabre under this Agreement (other than to Forest, which shall instead be subject to the following provisions) such that such
sub-licensee shall assume all rights and obligations of Cypress under this Agreement. In addition, any rights granted to Cypress pursuant to this Agreement shall survive early termination
of this Agreement by Pierre Fabre and become direct rights granted from Pierre Fabre to Forest under this Agreement with respect to the applicable territory if: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Forest becomes a direct licensee from Pierre Fabre pursuant to Section&nbsp;14.3(b)(iv)&nbsp;of the Restated License
Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;such early termination of this Agreement by Pierre Fabre occurred pursuant to
(1)&nbsp;Section&nbsp;10.2(a)(i)&nbsp;or 10.2(d), or (2)&nbsp;Section&nbsp;10.2(a)(ii)&nbsp;if Forest (including any Affiliate of Forest that is primarily responsible for the activities of
Forest under the Collaboration Agreement) did not cause the breach of any material provision of this Agreement by Cypress that resulted in such early termination and cures any such payment breach by
Cypress to the extent related to the jurisdictions in which Forest holds a sub-license from Cypress, or (3)&nbsp;Section&nbsp;10.2(c) if Forest (including any Affiliate of Forest that
is primarily responsible for the activities of Forest under the Collaboration Agreement) is not the Third Party that acquired Cypress in such Change in Control transaction that resulted in such early
termination; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Forest agrees to assume the obligations of Cypress under this Agreement in writing, there is no evidence that an event
has occurred or condition exists that would be reasonably likely to result in an event of default by Forest under the terms of this Agreement over the year following the effective date of the early
termination, and the scope of the sub-license to Forest under the License Agreement is substantially similar to that reflected in the Collaboration Agreement as of the date hereof, unless
amended with Pierre Fabre's consent. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;In the event that, upon expiration of the Term, this Agreement is not extended pursuant to Section&nbsp;10.1, then all
rights granted to Cypress hereunder shall terminate as of the last day of the Term, except as provided in Section&nbsp;10.3(c), and Cypress, its Affiliates and sub-licensees shall cease
all use of the Manufacturing Know-How and shall comply with the provisions of Section&nbsp;11.1 with respect to Pierre Fabre's Confidential Information. However, in the event that this
Agreement </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=22,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=94632,FOLIO='22',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_ls1113_1_23"> </A>
<UL>

<P><FONT SIZE=2>is
not extended because Pierre Fabre is unable or unwilling to agree to the same financial terms as set forth herein at the time such negotiation occurs and there is no qualified supplier of API then
able to supply API on commercially reasonable terms, then the provisions of Section&nbsp;8.11(b), (c), (d)&nbsp;and (e)&nbsp;shall apply, as if the Manufacturing Right had been duly exercised
under those sections, and shall survive the expiration of this Agreement, except that, in such a case, Cypress shall reimburse Pierre Fabre for its reasonable and documented costs associated with the
transfer of the Manufacturing Know-How, including the assistance provided by Pierre Fabre if requested by Cypress. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All licenses granted under this Agreement will be deemed licenses of rights to intellectual property for purposes of
Section&nbsp;365(n) of the U.S. Bankruptcy Code and a licensee under this Agreement will retain and may fully exercise all of its rights and elections under the US Bankruptcy Code. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Right to Terminate.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The use by either party hereto of a termination right provided for under
this Agreement shall not give rise to the payment of damages or any other form of compensation or relief to the other party with respect thereto. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5&nbsp;&nbsp;&nbsp;&nbsp;Damages; Relief.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in this Agreement, termination of this Agreement shall not
preclude either party from claiming any other damages, compensation or relief that it may be entitled to upon such termination. </FONT></P>

<P><FONT SIZE=2><B>11.&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B>GENERAL PROVISIONS.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1&nbsp;&nbsp;&nbsp;&nbsp;Dispute Resolution and Arbitration.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a dispute arising in connection with this Agreement,
the provisions set forth as Sections 16.1 and 16.2 of the Restated License Agreement shall apply; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that the reference to
Section&nbsp;9.3 in Section&nbsp;16.2(a) of the Restated License Agreement shall be deemed to refer to Section&nbsp;7.4(f) of this Agreement for purposes of applying such provisions to a dispute
arising under this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pierre Fabre and Cypress agree that the provisions of Section&nbsp;13 of the Restated
License Agreement regarding the obligations of both Pierre Fabre and Cypress with respect to Confidential Information shall also govern the parties' obligations under this Agreement. Further, the
parties agree that the term </FONT><FONT SIZE=2><B><I>"Confidential Information"</I></B></FONT><FONT SIZE=2> as defined in the Restated License Agreement shall also include all information furnished to it
by the other party pursuant to this Agreement, including Manufacturing Know-How which may be disclosed by Pierre Fabre to Cypress. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by, and construed and enforced in accordance with, the laws
of the State of New York excluding its conflicts of laws principles. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.4&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement; Modification.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is both a final expression of the parties' agreement and a
complete and exclusive statement with respect to all of its terms. The Exhibits referred to in this Agreement are incorporated herein and made a part of this Agreement by this reference. No rights or
licenses with respect to any intellectual property of either party are granted or deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement. No
trade customs, courses of dealing or courses of performance by the parties shall be relevant to modify, supplement or explain any term(s) used in this Agreement. This Agreement may not be modified or
supplemented by any purchase order, change order, acknowledgment, order acceptance, standard terms of sale, invoice or the like. This Agreement may only be modified or supplemented in a writing
expressly stated for such purpose and signed by the parties to this Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=23,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=150035,FOLIO='23',FILE='DISK043:[04SAN3.04SAN1113]LS1113A.;8',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<BR>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_lt1113_1_24"> </A> </FONT></P>

<!-- TOC_END -->

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.5&nbsp;&nbsp;&nbsp;&nbsp;Relationship Between the Parties.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties' relationship, as established by this Agreement, is solely
that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the parties. Neither party is a legal representative of the
other party, and neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.6&nbsp;&nbsp;&nbsp;&nbsp;Non-Waiver.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The failure of a party to insist upon strict performance of any provision of this
Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance
or in any other instance. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall
be signed by such party. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.7&nbsp;&nbsp;&nbsp;&nbsp;Assignment.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly provided hereunder, neither this Agreement nor any rights or obligations
hereunder may be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld); </FONT> <FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that either
party may assign this Agreement and its rights and obligations hereunder without the other party's consent in connection
with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; </FONT> <FONT SIZE=2><I>providing,</I></FONT><FONT
SIZE=2> that any assignment made by Cypress shall be made in full compliance with the provisions of Section&nbsp;11.8
"</FONT><FONT SIZE=2><B><I>Change of Control</I></B></FONT><FONT SIZE=2><I>.</I></FONT><FONT SIZE=2>" In the event of such transaction, however, intellectual property rights of the acquiring party to such
transaction (if other than one of the parties to this Agreement) shall not be included in the technology licensed hereunder. The rights and obligations of the parties under this Agreement shall be
binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Agreement shall be void. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.8&nbsp;&nbsp;&nbsp;&nbsp;Change of Control.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a proposed Change in Control, Cypress shall provide Pierre Fabre with
prior notice of at least 10 business days of such proposed Change in Control. If Pierre Fabre reasonably determines that the Third Party acquiror in such Change in Control is not likely to comply with
the terms of this Agreement, Pierre Fabre may request reasonable assurances from such Third Party acquiror regarding its intent to comply with the terms of this Agreement by providing written notice
of such request within five business days after the date of the notice from Cypress. If Pierre Fabre does not make such request within such period, this Agreement will remain in full force and effect.
If Pierre Fabre makes such request within such period, then (a)&nbsp;if such Third Party acquiror provides Pierre Fabre reasonable assurances in writing of its intent to comply with the terms of
this Agreement no later than the closing of the Change in Control, then this Agreement will remain in full force and effect, and (b)&nbsp;if such Third Party acquiror does not provide Pierre Fabre
reasonable assurances in writing of its intent to comply with the terms of this Agreement by the closing of the Change in Control, then Pierre Fabre may terminate this Agreement pursuant to
Section&nbsp;10.2(c). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.9&nbsp;&nbsp;&nbsp;&nbsp;No Third Party Beneficiaries.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is neither expressly nor impliedly made for the benefit of any
party other than those executing it. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.10&nbsp;&nbsp;&nbsp;&nbsp;Severability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or
illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement.
All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.11&nbsp;&nbsp;&nbsp;&nbsp;Notices.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any notice to be given under this Agreement must be in writing and delivered either in person, by
any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at its address(es) given
below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a)&nbsp;the date </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=24,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=380589,FOLIO='24',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_25"> </A>
<BR>

<P><FONT SIZE=2>of
actual receipt; (b)&nbsp;if mailed, three calendar days after the date of postmark; or (c)&nbsp;if delivered by overnight courier or by facsimile, the next business day the overnight courier
regularly makes deliveries or on the day after the facsimile has been sent. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to Pierre Fabre, notices must be addressed to: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Pierre
Fabre M&eacute;dicament<BR>
Parc Industriel de la Chartreuse 1<BR>
81106 Castres, C&eacute;dex<BR>
France<BR>
Attention:&nbsp;&nbsp;Chief Operating Officer<BR>
Telephone:&nbsp;&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2><BR>
Facsimile:&nbsp;&nbsp;(33)&nbsp;5 63 71 45 34 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
a copy to: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Pierre
Fabre M&eacute;dicament<BR>
La Chartreuse I<BR>
81106 Castres, C&eacute;dex<BR>
France<BR>
Attention:&nbsp;&nbsp;General Counsel<BR>
Telephone:&nbsp;&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT><FONT SIZE=2><BR>
Facsimile:&nbsp;&nbsp;(33)&nbsp;5 63 71 39 90 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to Cypress, notices must be addressed to: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Cypress
Bioscience,&nbsp;Inc.<BR>
4350 Executive Drive, Suite 325<BR>
San Diego, CA 92121<BR>
Attention:&nbsp;&nbsp;Jay D. Kranzler<BR>
Telephone:&nbsp;&nbsp;(858)&nbsp;452-2323<BR>
Facsimile:&nbsp;&nbsp;(858)&nbsp;452-1222 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
a copy to: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Cooley
Godward LLP<BR>
4401 Eastgate Mall<BR>
San Diego, CA 92121<BR>
Attention:&nbsp;&nbsp;Kay Chandler<BR>
Telephone:&nbsp;&nbsp;(858)&nbsp;550-6000<BR>
Facsimile:&nbsp;&nbsp;(858)&nbsp;550-6420 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.12&nbsp;&nbsp;&nbsp;&nbsp;Force Majeure.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for the obligation to make payment when due, each party shall be excused from
liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such party's reasonable control including but not limited to Acts of God, fire,
flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of
raw materials, any strike or labor disturbance, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s)
causing the failure or delay in performance and provided that the party has not caused such event(s) to occur. Notice of a party's failure or delay in performance due to force majeure must be given to
the other party within ten calendar days after its occurrence. In no event shall any party be required to prevent or settle any labor disturbance or dispute. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.13&nbsp;&nbsp;&nbsp;&nbsp;Legal Fees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If any party to this Agreement resorts to any legal action, dispute resolution or arbitration
in connection with this Agreement, then, subject to Section&nbsp;11.1 of this Agreement and </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=25,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=221618,FOLIO='25',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_26"> </A>

<P><FONT SIZE=2>Section&nbsp;16.2
of the Restated License Agreement, the prevailing party shall be entitled to recover reasonable fees of attorneys and other professionals in addition to all court costs and
arbitrator's fees which that party may incur as a result. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.14&nbsp;&nbsp;&nbsp;&nbsp;Interpretation.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Captions&nbsp;&amp; Headings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The captions and headings of
clauses contained in this Agreement preceding the text of the articles, sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not
constitute any part of this Agreement, or have any effect on its interpretation or construction. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Singular&nbsp;&amp; Plural.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All references in this Agreement
to the singular shall include the plural where applicable, and all references to gender shall include both genders and the neuter. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Articles, Sections&nbsp;&amp; Subsections.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise
specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all
subsections and paragraphs in such sections; and references in this Agreement to any subsection shall include all paragraphs in such subsection. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Days.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All references to days in this Agreement shall mean
calendar days, unless otherwise specified. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Ambiguities.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ambiguities and uncertainties in this
Agreement, if any, shall not be interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.15&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original document, and all of which, together with this writing, shall be deemed one instrument. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>IN WITNESS WHEREOF,</B></FONT><FONT SIZE=2> the parties hereto have each caused this Agreement to be signed and delivered by its duly authorized officer or
representative as of the date first set forth above. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><BR><FONT SIZE=2><B>PIERRE FABRE M&Eacute;DICAMENT</B></FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><B><BR>
CYPRESS BIOSCIENCE,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JEAN PIERRE COUZINIER</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JAY KRANZLER</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
Jean Pierre Couzinier</FONT><HR NOSHADE></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
Dr.&nbsp;Jay Kranzler</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="39%"><BR><FONT SIZE=2><I>Chief Operating Officer</I></FONT><HR NOSHADE></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="39%"><BR><FONT SIZE=2><I>Chief Executive Officer</I></FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=26,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=549242,FOLIO='26',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_27"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="lt1113_exhibit_i_milnacipran_hydrochl__exh02185"> </A>
<A NAME="toc_lt1113_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT I    <BR>    <BR>    Milnacipran hydrochloride<BR>  US DMF # 11501&#151;Specifications    <BR>    </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>[...***...]</B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B>*Confidential Treatment Requested  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=27,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=1042941,FOLIO='27',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_28"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><B>[...***...]</B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B>*Confidential Treatment Requested  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=28,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=811627,FOLIO='28',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_29"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="lt1113_exhibit_ii_responsibilities_of_the_working_group"> </A>
<A NAME="toc_lt1113_2"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT II    <BR>    <BR>    RESPONSIBILITIES OF THE WORKING GROUP    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B>*Confidential Treatment Requested  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=29,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=930842,FOLIO='29',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_30"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="lt1113_exhibit_iii_example_of_changes_in_forecasts"> </A>
<A NAME="toc_lt1113_3"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT III    <BR>    <BR>    Example of changes in forecasts    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>[...***...]</B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B>*Confidential Treatment Requested  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=30,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=895431,FOLIO='30',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<A NAME="page_lt1113_1_31"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="lt1113_exhibit_iv_quality_agreement_e__exh03420"> </A>
<A NAME="toc_lt1113_4"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT IV    <BR>    <BR>    Quality Agreement Example    <BR>    <BR>    QUALITY AGREEMENT (QA) TABLE OF CONTENTS GUIDELINE    <BR>    </B></FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><B>I.</B></FONT></DT><DD><FONT SIZE=2><B>Quality Control/Quality Assurance/Regulatory</B></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>A.</FONT></DT><DD><FONT SIZE=2>Regulatory
Requirements </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>B.</FONT></DT><DD><FONT SIZE=2>Regulatory
Annual Report </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>C.</FONT></DT><DD><FONT SIZE=2>Regulatory
Drug Listing </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>D.</FONT></DT><DD><FONT SIZE=2>Regulatory
Drug Master Files (DMF) </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>E.</FONT></DT><DD><FONT SIZE=2>FDA
and Regulatory Agencies Inquires / Inspections / Notifications<BR>
&#149;&nbsp;&nbsp;&nbsp;&nbsp;Communication and Support Process<BR>
&#149;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Inspections, Inspection Observations (483),Warning Letter, Recall </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>F.</FONT></DT><DD><FONT SIZE=2>External
Audits: Periodic GMP Assessments of Supplier </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>G.</FONT></DT><DD><FONT SIZE=2>Internal
Audits: Suppliers Self Inspection/Audit Program </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>H.</FONT></DT><DD><FONT SIZE=2>Product
and Process Qualification </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>I.</FONT></DT><DD><FONT SIZE=2>Training/Qualification
Program </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>J.</FONT></DT><DD><FONT SIZE=2>Batch
(Lot) Numbers </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>K.</FONT></DT><DD><FONT SIZE=2>Incoming
Raw Material/Component Inspections and Control </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>L.</FONT></DT><DD><FONT SIZE=2>Equipment
Calibration, Qualification and Maintenance </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>M.</FONT></DT><DD><FONT SIZE=2>QA
Presence in Facility </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>N.</FONT></DT><DD><FONT SIZE=2>Product
Expiration Dating Assignment and Storage Conditions </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>O.</FONT></DT><DD><FONT SIZE=2>In-Process
Controls </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>P.</FONT></DT><DD><FONT SIZE=2>Laboratory
Analysis </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>Q.</FONT></DT><DD><FONT SIZE=2>Non-Conforming
or Rejected Material </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>R.</FONT></DT><DD><FONT SIZE=2>Deviations
and Lab 00S Investigations </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>S.</FONT></DT><DD><FONT SIZE=2>Finished
Product Release and Shipping Requirements </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>T.</FONT></DT><DD><FONT SIZE=2>Retain
Samples </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>U.</FONT></DT><DD><FONT SIZE=2>Batch
Documentation and Quality Records </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>V.</FONT></DT><DD><FONT SIZE=2>Printed
Package Materials (PPM) </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>W.</FONT></DT><DD><FONT SIZE=2>Destroy
Order System for Printed Components </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>X.</FONT></DT><DD><FONT SIZE=2>Change
Notification and Change Control </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>Y.</FONT></DT><DD><FONT SIZE=2>Stability
</FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>Z.</FONT></DT><DD><FONT SIZE=2>Product
Complaints and Adverse Drug Events (ADE) </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>AA.</FONT></DT><DD><FONT SIZE=2>Annual
Product Quality Review (PPQE) </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>BB.</FONT></DT><DD><FONT SIZE=2>Specifications
and Specification Change Request </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>CC.</FONT></DT><DD><FONT SIZE=2>Laboratory
Methods, Methods Validation, Method Transfer and Laboratory Method/Specifications Change Request </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>DD.</FONT></DT><DD><FONT SIZE=2>Reference
Standard </FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>EE.</FONT></DT><DD><FONT SIZE=2>Subcontracting
and Component Vendors<BR>
&#149;&nbsp;&nbsp;&nbsp;&nbsp;Approved Supplier List for Raw Materials<BR>
&#149;&nbsp;&nbsp;&nbsp;&nbsp;Approval/Evaluation Process<BR>
&#149;&nbsp;&nbsp;&nbsp;&nbsp;Right to Use or Not Use Comments </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=31,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5",CHK=774543,FOLIO='31',FILE='DISK043:[04SAN3.04SAN1113]LT1113A.;9',USER='JKEENE',CD='28-MAR-2004;14:31' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04SAN1113_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_lq1113_1">Exhibit 10.25</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_lt1113_1">EXHIBIT I Milnacipran hydrochloride US DMF # 11501&#151;Specifications</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_lt1113_2">EXHIBIT II RESPONSIBILITIES OF THE WORKING GROUP</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_lt1113_3">EXHIBIT III Example of changes in forecasts</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_lt1113_4">EXHIBIT IV Quality Agreement Example QUALITY AGREEMENT (QA) TABLE OF CONTENTS GUIDELINE</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=TDUNNIG,SEQ=,EFW="2131468",CP="CYPRESS BIOSCIENCE, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
